Loading...

Home
ETF
SCYX

SCYX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

SCYX News

U.S. March Manufacturing PMI Slightly Rises

Apr 01 2026seekingalpha

SCYNEXIS Secures $40M in Securities Purchase Agreement

Mar 31 2026seekingalpha

Scynexis Acquires Kidney Disease Treatment, Shares Surge

Mar 31 2026stocktwits

Poxel SA Sells Drug Candidate PXL770 to Scynexis for Up to $196 Million

Mar 31 2026NASDAQ.COM

Poxel Enters Drug Agreement with SCYNEXIS for PXL770

Mar 31 2026Newsfilter

SCYNEXIS Reports 2025 Financial Highlights and Pipeline Progress

Mar 05 2026NASDAQ.COM

SCYNEXIS Secures FDA QIDP Designation for SCY-247, Ensuring 10 Years of Market Exclusivity

Jan 21 2026Yahoo Finance

Scynexis Reveals Federal Support for Partnership Between Hackensack Meridian CDI and Johns Hopkins Researchers to Create Innovative Therapies, Including New Fungerps, for Resistant Fungal Infections

Nov 17 2025Newsfilter

SCYNEXIS Announces Financial Results for Q3 2025 and Shares Corporate Update

Nov 05 2025Newsfilter

Guggenheim Reiterates Buy Rating on SCYNEXIS, Adjusts Price Target to $3

Oct 28 2025Benzinga

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

Oct 23 2025NASDAQ.COM

SCYNEXIS Announces Encouraging Phase 1 Findings for Antifungal Candidate SCY-247

Sep 30 2025NASDAQ.COM

SCYNEXIS to Attend the H.C. Wainwright 27th Annual Global Conference from September 8 to 10, 2025

Aug 25 2025Newsfilter

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15 2025Newsfilter

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Apr 08 2025Newsfilter

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12 2025Newsfilter